Tumors With AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy With AKT Inhibitors

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-15-0230
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Combination Therapy With BRAF and MEK Inhibitors for Melanoma: Latest Evidence and Place in Therapy

Therapeutic Advances in Medical Oncology
Oncology
2015English

Potent Antitumor Effect of Combination Therapy With Sub‑optimal Doses of Akt Inhibitors and Pomalidomide Plus Dexamethasone in Multiple Myeloma

Oncology Letters
Cancer ResearchOncology
2018English

Synthetic Sickness or Lethality Points at Candidate Combination Therapy Targets in Glioblastoma

International Journal of Cancer
Cancer ResearchOncology
2013English

Inhibition of AKT Pathway Augments Combination Therapy

Otolaryngology - Head and Neck Surgery
OtorhinolaryngologySurgery
2010English

Single Agent Therapy With Bevacizumab for the Treatment of Atypical Choroid Plexus Tumor

Kansas Journal of Medicine
2015English

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors

Journal of Clinical Medicine Research
2019English

Heterogeneity Within AML With CEBPA Mutations; Only CEBPA Double Mutations, but Not Single CEBPA Mutations Are Associated With Favourable Prognosis

British Journal of Cancer
Cancer ResearchOncology
2009English

Venetoclax as a Single Agent and in Combination With PI3K-MTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2018English

Combating Antimicrobial Resistance- Utility of Antimicrobial Combination Therapy and / or Β-Lactamase Inhibitors

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy